ART558-induced SL and a combination effect with olaparib werealso observed in isogenic models of BRCA1-deficientcells, and ART558 sensitivity was observed in tumor celllines with pathogenic BRCA1 mutations, suggestingthat these effects are not specific to BRCA2 mutantcells, but also extend to BRCA1 mutant tumor cells.Importantly, cell growth inhibition of BRCA1 or BRCA2 mutant cells was achieved at ART558 concentrationsthat had minimal effects in nontumor epithelial cells or BRCA2wt tumor cells. The gene discussed is BRCA2; the disease is neoplasm.